Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

GTO ID GTC0447
Trial ID NCT03610724
Disease Non-Hodgkin's Lymphoma
Altered gene CD19
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment Kymriah|Tisagenlecleucel
Generation2nd
PhasePhase2
Recruitment statusCompleted
TitlePhase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
Year2018
CountryUnited States
Company sponsorNovartis Pharmaceuticals
Other ID(s)CCTL019C2202|2017-005019-15
Vector information
Vectorlentivirus
ConstructscFv-4-1BB-CD3ζ

Clinical Result

Cohort 1
Administration route intravenous infusion
Dosage ≤50kg: 0.2~5E6 cells/kg, >50kg: 0.1~2.5E8 cells
Donor type Autologous
Pts 33
Age Child, Adult
Lymph depletion Yes
Outcome Overall Response Rate (ORR) as Determined by Local Investigator:32.1%
Adverse reactions 17/33(All-cause Mortality); 24/33(Blood and lymphatic system disorders; Cardiac disorders; Eye disorders; Gastrointestinal disorders; General disorders; Immune system disorders; Infections and infestations; Musculoskeletal and connective tissue disorders; Nervous system disorders; Renal and urinary disorders; Respiratory, thoracic and mediastinal disorders; Vascular disorders)

Relationship Graph

Overview of Knowledge Graph